Activation of GABA-B receptors induced by systemic amphetamine abolishes dopamine release in the rat lateral septum.
The lateral septum is a brain nucleus involved in various mental disorders such as anxiety and drug addiction. In the present study, we investigated whether systemic amphetamine, known to release dopamine (DA) in nucleus accumbens, will also release DA in lateral septum. Our results show that systemic amphetamine administration (2 mg/kg i.p.) induced a significant increase in DA extracellular levels in nucleus accumbens but not in lateral septum. Interestingly, intralateral septum perfusion of amphetamine through the microdialysis probe induced a significant increase in DA extracellular levels. To test if GABAergic neurotransmission in lateral septum was responsible for inhibiting the release of DA when amphetamine was administered systemically, we perfused a GABA-B selective antagonist (CGP-52432) intra lateral septum. Systemic amphetamine administration induced a significant increase in lateral septum DA release when CGP-52432 was concomitantly superfused. Our results indicate that the systemic administration of amphetamine induces an increase in lateral septum GABA release and the consequent activation of GABA-B receptors counteracting the direct effect of amphetamine on lateral septum DA release.
Sotomayor-Zárate
Ramón
R
Millennium Science Nucleus in Stress and Addiction and Department of Cell and Molecular Biology, Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile.
Araya
Katherine Angélica
KA
Pereira
Paulo
P
Blanco
Elías
E
Quiroz
Gabriel
G
Pozo
Sergio
S
Carreño
Paz
P
Andrés
María Estela
ME
Forray
María Inés
MI
Gysling
Katia
K
D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D001596:Benzylamines / Q000494:pharmacology; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D003956:Dialysis; D004298:Dopamine / Q000378:metabolism*; D005110:Extracellular Space / Q000378:metabolism; D058786:GABA-B Receptor Agonists; D058788:GABA-B Receptor Antagonists; D005968:Glutamate Decarboxylase / Q000235:genetics / Q000378:metabolism; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism; D010477:Perfusion; D010721:Phosphinic Acids / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D020665:Septum of Brain / Q000187:drug effects* / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D001596:Benzylamines; D000697:Central Nervous System Stimulants; D058786:GABA-B Receptor Agonists; D058788:GABA-B Receptor Antagonists; D010721:Phosphinic Acids; D012333:RNA, Messenger; C083008:CGP 52432; D005680:gamma-Aminobutyric Acid; D000661:Amphetamine; D005968:Glutamate Decarboxylase; C402565:glutamate decarboxylase 1; C401141:glutamate decarboxylase 2; D004298:Dopamine